Navigation Links
Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:8/4/2008

ine results with boceprevir are very exciting, especially given that genotype 1 is the most common and hardest to treat form of hepatitis C," said Paul Kwo, M.D., associate professor of medicine and medical director, liver transplantation, Department of Medicine, Division of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, and lead investigator of the study. "Boceprevir was well tolerated by patients in this study, including those who received 48 weeks of boceprevir in the longer duration treatment arms."

Safety data from the study showed that the most common adverse events reported in the boceprevir arms were fatigue, anemia, nausea and headache. No increase in skin adverse events (rash or pruritus) beyond what was seen in the PEGINTRON and REBETOL control arm was observed. Treatment discontinuations due to adverse events were between 9 and 19 percent for patients in the boceprevir arms, compared to 8 percent for the control arm.

In the study, known as HCV SPRINT-1 (HCV Serine Protease Inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated in three treatment regimens: 4 weeks of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) therapy followed by the addition of boceprevir to the combination for 24 or 44 weeks (totaling 28 or 48 weeks of treatment); boceprevir in combination with PEGINTRON and REBETOL at the doses described above for 28 or 48 weeks; and boceprevir in combination with PEGINTRON and low-dose REBETOL (400-1000 mg daily) for 48 weeks, compared to a control of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) alone for 48 weeks (an approved treatment regimen). The primary endpoint of the study is SVR after 24 weeks of follow up (SVR 24). This is an ongoing study and SVR 24 rates are not yet available for patients in the 48-week boceprevir arms or the 48-week control arm of the study.

Sustai
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
2. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
3. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
4. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
5. Inspires Phase 3 CF Trial, Using PARIs Nebulizer & Compressor, Shows Positive Top-Line Results
6. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
7. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
8. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
9. Schering-Plough Reports Top-Line Results of the IDEAL Study
10. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
11. Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... 2010 MMRSS, which has been,expanding its geographic footprint over the past 5 years, announced the,opening of ... , , ... Thailand , Indonesia , Sri,Lanka , Bangladesh , Vietnam and UAE, has ... , , ...
... , SUNNYVALE, Calif. , Aug. 3 Accuray Incorporated ... field of radiosurgery, announced today it received Shonin approval from the Japanese ... Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive ... as the "CyberKnife® Radiosurgery System." , ...
Cached Medicine Technology:MMRSS now in Hong Kong, Singapore and Taiwan 2Accuray's CyberKnife® G4 System Receives Shonin Approval 2Accuray's CyberKnife® G4 System Receives Shonin Approval 3Accuray's CyberKnife® G4 System Receives Shonin Approval 4
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
(Date:4/17/2014)... research team led by Cesar A. Arias, M.D., Ph.D., ... Houston (UTHealth) has identified a new superbug that caused ... appeared in the April 17 issue of The ... superbug is part of a class of highly-resistant bacteria ... which is a major cause of hospital and community-associated ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... predictive models of human disease is likely following ... (ESF), which urged for a collaborative effort between ... an enormous amount of data from different sources ... of human tissue, and in vitro laboratory experiments. ...
... WASHINGTON, Nov. 12 The Service Employees,International Union (SEIU), ... the following statement in support of the diagnosis of,and ... by,Senator Max Baucus (D-MT) today:, On the heels ... their top overall issues -- and health care costs ...
... as Rainmakers, SAN DIEGO, Nov. 12 New ... of nurses as hospital revenue,generators, according to a new ... staffing company in,the nation, the survey of 305 hospital ... and the emerging role of nurses as,financial rainmakers., ...
... Pharmaceuticals Inc.,announces the promotion of William N. ... Orthopaedics and Urology Business Unit, recently formed ... formerly Executive Director of,Ferring,s Orthopaedics Business Unit., ... In his new role, Garbarini is responsible ...
... components will feature its productivity maximizing products at ASCB Meeting in San ... ... 2008 -- InVitria InVitria announced today that it will showcase ... Biology Meeting on Dec. 13-17 in San Francisco, CA. InVitria provides animal ...
... record lows,the nation,s stress level hits record highs, but despite ... being more stressed,than ever. In his latest book, Life from ... advice such as, "don,t worry, just,stay calm," not only doesn,t ... problem is explained by new information on the nature of ...
Cached Medicine News:Health News:Computers make sense of experiments on human disease 2Health News:Computers make sense of experiments on human disease 3Health News:SEIU Statement in Support of New Blueprint to Solve Health Care Crisis by Senator Max Baucus 2Health News:AMN Survey: Nurses to Have Bigger Impact on Hospital Revenue 2Health News:Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit 2Health News:Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit 3Health News:InVitria to Showcase its Innovative Cell Culture Components at American Society of Cell Biology Annual Meeting 2Health News:InVitria to Showcase its Innovative Cell Culture Components at American Society of Cell Biology Annual Meeting 3Health News:Stress Spikes as Economy Tanks - Psychologist Identifies Why Traditional 'Stress Management' Techniques Don't Work, and Offers Radical New Approach 2
Pilling-Weck, medium clip size, 10mm, rotatable take apart...
Insert only, Ethicon, small clip size...
Ethicon, medium clip size, 10mm, rotatable take apart...
... The Wako CRP-HS assay utilizes turbidimetric ... procedure, measuring over the range of 0.2-28.0 ... can be adapted to most clinical chemistry ... performance in terms of precision, linearity, correlation, ...
Medicine Products: